Ms. Dawn Svoronos reports

THERATECHNOLOGIES APPOINTS ELINA TEA TO ITS BOARD OF DIRECTORS

Theratechnologies Inc. has appointed Elina Tea, chief financial officer at GLS North America, to its board of directors and as a member of the company's audit committee. Ms. Tea will be Investissement Quebec's designee pursuant to its investor rights agreement with the company.

"Elina Tea's extensive experience in finance, corporate strategy and investor relations makes her a valuable addition to our board of directors," said Dawn Svoronos, chair of the board of directors at Theratechnologies. "With her strong communications, strategic thinking and leadership skills, and her impressive track record in private and public financing, and M&A [merger and acquisition] transactions across a diverse range of industries, Ms. Tea has the demonstrated capacity to support the company's business initiatives. She brings a welcomed perspective to Theratechnologies as the company focuses on its commercial business, and the search for new products and partners."

"It's an honour to join the distinguished board of directors of Theratechnologies, and I look forward to contributing to the company's path to success and value creation," said Ms. Tea.

In her current role as chief financial officer at GLS North America, Ms. Tea oversees all operational and strategic matters with the finance, M&A [merger and acquisition], legal and human resources departments of the GLS Canada and GLS U.S. businesses. She previously served as chief financial officer at Vosker Corp. and vice-president, corporate development, at Cogeco Communications, and has amassed considerable financial and business development experience at a range of companies, including SNC-Lavalin (office of the president), Desjardins Group, RBC Capital Markets, and Ernst & Young corporate finance. She holds a bachelor of commerce degree, with a double concentration in accounting and finance, from McGill University and is a chartered financial analyst.

With the appointment of Ms. Tea, the company's audit committee will now comprise four independent members, including the recently appointed Jordan Zwick, Gerald Lacoste and Frank Holler as chair.

About Theratechnologies Inc.

Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs.

We seek Safe Harbor.